Global 16% Market Share and 80 Commercial Projects: Wuxi Apptec (02359) Adheres to Doing the Right Thing, with 167 Phase III and Commercialized Small Molecule Pipeline Projects

Stock News01-15

On January 14, 2026, Wuxi Apptec (603259.SH, 02359) delivered a keynote speech at the 44th annual J.P. Morgan Healthcare Conference, providing an update on its business progress. According to the disclosed data, as of the third quarter of 2025, the company's total small-molecule CDMO pipeline reached 3,430 projects, accounting for 16% of the global new drug pipeline in clinical stages; within this, Phase III and commercialized projects have reached 167.

The company reviewed the number of Phase III and commercialized projects and their corresponding revenue generated in recent years. Since 2022, the number of molecules in Phase III and commercialization has grown from 107 to 167, a significant increase of 56%. Corresponding revenue surged from 4.7 billion yuan to 10.3 billion yuan in 2024, with this year's figures expected to reach a new high.

Recently, oral drugs, leveraging their significant advantage of convenient administration, are rapidly replacing injectables across major global therapeutic areas, emerging as a new focal point in the pharmaceutical industry. Just recently, the industry media Endpoints News listed "Pills" as one of the keywords for 2025, highlighting the strong rise of this segment—from lipid-lowering drugs and psoriasis treatments to next-generation weight-loss medications, oral formulations are continuously expanding into areas like obesity, heart disease, and inflammatory diseases, steadily capturing market share previously dominated by large-molecule biologics.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1174529453?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-15 08:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174529453","market":"sh","top_or_hot":-1,"title":"Global 16% Market Share and 80 Commercial Projects: Wuxi Apptec (02359) Adheres to Doing the Right Thing, with 167 Phase III and Commercialized Small Molecule Pipeline Projects","media":"Stock News","content":"<p>On January 14, 2026, Wuxi Apptec (603259.SH, 02359) delivered a keynote speech at the 44th annual J.P. Morgan Healthcare Conference, providing an update on its business progress. According to the disclosed data, as of the third quarter of 2025, the company's total small-molecule CDMO pipeline reached 3,430 projects, accounting for 16% of the global new drug pipeline in clinical stages; within this, Phase III and commercialized projects have reached 167.</p>\n<p>The company reviewed the number of Phase III and commercialized projects and their corresponding revenue generated in recent years. Since 2022, the number of molecules in Phase III and commercialization has grown from 107 to 167, a significant increase of 56%. Corresponding revenue surged from 4.7 billion yuan to 10.3 billion yuan in 2024, with this year's figures expected to reach a new high.</p>\n<p>Recently, oral drugs, leveraging their significant advantage of convenient administration, are rapidly replacing injectables across major global therapeutic areas, emerging as a new focal point in the pharmaceutical industry. Just recently, the industry media Endpoints News listed \"Pills\" as one of the keywords for 2025, highlighting the strong rise of this segment—from lipid-lowering drugs and psoriasis treatments to next-generation weight-loss medications, oral formulations are continuously expanding into areas like obesity, heart disease, and inflammatory diseases, steadily capturing market share previously dominated by large-molecule biologics.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Global 16% Market Share and 80 Commercial Projects: Wuxi Apptec (02359) Adheres to Doing the Right Thing, with 167 Phase III and Commercialized Small Molecule Pipeline Projects</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlobal 16% Market Share and 80 Commercial Projects: Wuxi Apptec (02359) Adheres to Doing the Right Thing, with 167 Phase III and Commercialized Small Molecule Pipeline Projects\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-15 08:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On January 14, 2026, Wuxi Apptec (603259.SH, 02359) delivered a keynote speech at the 44th annual J.P. Morgan Healthcare Conference, providing an update on its business progress. According to the disclosed data, as of the third quarter of 2025, the company's total small-molecule CDMO pipeline reached 3,430 projects, accounting for 16% of the global new drug pipeline in clinical stages; within this, Phase III and commercialized projects have reached 167.</p>\n<p>The company reviewed the number of Phase III and commercialized projects and their corresponding revenue generated in recent years. Since 2022, the number of molecules in Phase III and commercialization has grown from 107 to 167, a significant increase of 56%. Corresponding revenue surged from 4.7 billion yuan to 10.3 billion yuan in 2024, with this year's figures expected to reach a new high.</p>\n<p>Recently, oral drugs, leveraging their significant advantage of convenient administration, are rapidly replacing injectables across major global therapeutic areas, emerging as a new focal point in the pharmaceutical industry. Just recently, the industry media Endpoints News listed \"Pills\" as one of the keywords for 2025, highlighting the strong rise of this segment—from lipid-lowering drugs and psoriasis treatments to next-generation weight-loss medications, oral formulations are continuously expanding into areas like obesity, heart disease, and inflammatory diseases, steadily capturing market share previously dominated by large-molecule biologics.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2328871848.SGD","symbol_name":"Eastspring Investments - China A Shares Growth AS SGD","start_time":0,"source_url":"","article_id":"1174529453","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174529453","pubTimestamp":1768438019,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"On January 14, 2026, Wuxi Apptec (603259.SH, 02359) delivered a keynote speech at the 44th annual J.P. Morgan Healthcare Conference, providing an update on its business progress. According to the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"603259":"药明康德","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1997245177.USD":"安联神洲A股基金","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","LU1808992512.USD":"AB ALL CHINA EQUITY PORTFOLIO \"A\" (USD) ACC","02359":"药明康德","LU0456842615.SGD":"JPMorgan Funds - Emerging Markets Equity A (acc) SGD","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2045819591.USD":"Natixis WCM Global Emerging Markets Equity R/A USD","LU0052750758.USD":"富兰克林中国基金A Acc","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU2125910500.SGD":"Natixis WCM Global Emerging Markets Equity H-R/A SGD","LU1934453819.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"A\" (USD) ACC","LU1979443071.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"AD\" (USDHDG) INC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU1046422090.SGD":"Fidelity Pacific A-SGD","BK1583":"高瓴概念","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","BK0216":"研究试验","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD"},"translate_title":"全球16%市占率80个商业化项目：药明康德（02359）坚持做正确的事，167个III期及商业化小分子管线项目","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603259":1,"02359":1},"content_text":"On January 14, 2026, Wuxi Apptec (603259.SH, 02359) delivered a keynote speech at the 44th annual J.P. Morgan Healthcare Conference, providing an update on its business progress. According to the disclosed data, as of the third quarter of 2025, the company's total small-molecule CDMO pipeline reached 3,430 projects, accounting for 16% of the global new drug pipeline in clinical stages; within this, Phase III and commercialized projects have reached 167.\nThe company reviewed the number of Phase III and commercialized projects and their corresponding revenue generated in recent years. Since 2022, the number of molecules in Phase III and commercialization has grown from 107 to 167, a significant increase of 56%. Corresponding revenue surged from 4.7 billion yuan to 10.3 billion yuan in 2024, with this year's figures expected to reach a new high.\nRecently, oral drugs, leveraging their significant advantage of convenient administration, are rapidly replacing injectables across major global therapeutic areas, emerging as a new focal point in the pharmaceutical industry. Just recently, the industry media Endpoints News listed \"Pills\" as one of the keywords for 2025, highlighting the strong rise of this segment—from lipid-lowering drugs and psoriasis treatments to next-generation weight-loss medications, oral formulations are continuously expanding into areas like obesity, heart disease, and inflammatory diseases, steadily capturing market share previously dominated by large-molecule biologics.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1174529453","isCrawlerRequest":true}